


New immunotherapy targeting tumor macrophages to tackle lung cancer

May 8 2023



RimAb modifies the intratumoral myeloid cell compartment in a mouse model of LLC. a) Myeloid cell gating classification using the expression of surface markers CD45, CD11b, Ly6C, Ly6G, and MHCII. b) Percentage of CD45⁺CD11b⁺Ly6C^{hi}Ly6G^{hi} neutrophil population. c) Percentage of CD45⁺CD11b⁺Ly6C⁺Ly6G^{lo} myeloid cell subset. d) Percentage of CD45⁺CD11b⁺Ly6C^{lo}MHCII^{lo}, CD45⁺CD11b⁺Ly6C^{lo}MHCII^{hi}, CD45⁺CD11b⁺Ly6C^{hi}MHCII^{lo} and CD45⁺CD11b⁺Ly6C^{hi}MHCII^{hi} myeloid cell

subsets. e) Lymphoid cell gating classification using the expression of the CD45, CD3, CD8, CD4, CD25, NK1.1, and FoxP3 markers. f) Percentage of each lymphocytic subset population analyzed in control (isotype IgG2a) and RImAb-treated mice. Data are presented as the mean of \pm SEM (n = 8 per group), and statistical comparisons were performed using the Mann–Whitney t-test. Credit: *eBioMedicine* (2023). DOI: 10.1016/j.ebiom.2023.104555

Researchers from the Innate Immunity group at the Germans Trias i Pujol Research Institute (IGTP) have developed a new immunotherapy based on a monoclonal antibody directed against tumor macrophages. The results obtained lay the foundations for a new treatment for patients with lung cancer, with the potential to be applied to other solid tumors. The study has been published in the journal *eBioMedicine*.

Cancer is one of the leading causes of death worldwide, with nearly 10 million deaths in 2020 according to the World Health Organization. Although there are numerous treatments available, very few are truly curative. The problem lies in the ability of tumor cells to manipulate and educate the [immune system](#) so that it does not recognize them as malignant and works in their favor.

Immunotherapies aim to reactivate and re-educate the immune system to generate a robust anti-tumor response. These treatments have been a breakthrough for non-curable tumors, but still need improvement. In this context, [immune cells](#) called macrophages are a promising target in immuno-oncology, because tumor-associated macrophages (TAM macrophages) are immunosuppressive in most solid cancers, i.e., they weaken the immune system and reduce its effectiveness.

A recent study led by the Innate Immunity research group of the IGTP, under the direction of Dr. Maria Rosa Sarrias, shows the key role of the

CD5L protein in TAMs. The authors of the study, from different national and international centers, observed that a higher amount of this protein in macrophages is associated with a worse prognosis in lung [cancer](#) patients.

To address the problem, researchers have generated RImAb, a new antibody that specifically binds CD5L and reprograms macrophages. The antibody changes the way TAMs act, reducing their immunosuppressive capacity and endowing them with anti-tumor activity. This modifies the tumor microenvironment and reduces tumor growth in mice.

According to Dr. Sarrias, "the results open the door to a new line of treatment for [lung cancer](#) patients, with the potential to be applied to other solid tumors." This treatment will be further developed, and the research group plans to continue exploring the mechanism of action of the new immunotherapy, its application in other types of cancer, as well as its progression towards [clinical trials](#).

More information: Lidia Sanchez-Moral et al, Macrophage CD5L is a target for cancer immunotherapy, *eBioMedicine* (2023). [DOI: 10.1016/j.ebiom.2023.104555](#)

Provided by Germans Trias i Pujol Research Institute

Citation: New immunotherapy targeting tumor macrophages to tackle lung cancer (2023, May 8) retrieved 4 June 2024 from <https://medicalxpress.com/news/2023-05-immunotherapy-tumor-macrophages-tackle-lung.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--